GlassScriptPhysician profile
Paige L Bates
NPI 1861681025
$4,138.53
in general payments reported to CMS, 2019-2025
32 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $434 · 2021: $633 · 2022: $591 · 2023: $741 · 2024: $874 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $723.46 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $633.94 | 2019-2025 | Lokelma, Airsupra, Farxiga |
| Amgen INC. | $323.94 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $272.63 | 2022-2025 | |
| Lilly USA, LLC | $223.18 | 2019-2025 | Mounjaro, Jardiance |
| Abbvie INC. | $200.97 | 2021-2023 | Ubrelvy |
| Abbott Laboratories | $200.32 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $175.83 | 2019-2025 | |
| Dexcom, INC. | $174.19 | 2022-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $163.19 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $157.95 | 2020-2022 | |
| Abiomed | $148.89 | 2023 | Impella |
| Sanofi-Aventis U.S. LLC | $102.78 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $101.40 | 2020-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.88 | 2021-2024 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $65.16 | 2024 | Recorlev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.97 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $43.02 | 2019-2021 | |
| Glaxosmithkline, LLC. | $36.56 | 2023 | Arexvy, Shingrix |
| Nestle Healthcare Nutrition INC. | $34.68 | 2022 | |
| Horizon Therapeutics Plc | $33.39 | 2023 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $31.91 | 2022-2023 | Quviviq |
| Allergan, INC. | $23.58 | 2020 | |
| Acella Pharmaceuticals, LLC | $19.60 | 2025 | NP Thyroid 60 |
| Astellas Pharma US INC | $19.07 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.34 | 2024 | Caplyta |
| Ascensia Diabetes Care US INC. | $15.80 | 2023 | |
| Eisai INC. | $15.37 | 2022 | |
| Exact Sciences Corporation | $14.71 | 2023 | Cologuard Collection Kit |
| Corcept Therapeutics | $13.33 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.80 | 2020 | |
| Medtronic, INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.